Breaking News, Promotions & Moves

MC2 Therapeutics Appoints Trine Ahlgreen CEO

This transition reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion.

By: Rachel Klemovitch

Assistant Editor

MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, appointed Trine Ahlgreen as Chief Executive Officer. The transition to new leadership reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion. Ahlgreen will help expand its commercial asset, Wynzora Cream, and maximize the commercial potential of its formulation and drug delivery system, PAD Technology. Je...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters